BPC-157

Current reviews in musculoskeletal medicine · 2025

Researchers reviewed the potential benefits and safety of BPC-157, a synthetic peptide thought to aid in healing musculoskeletal injuries. While animal studies show promising regenerative effects, human research is very limited, with only a few small studies conducted and no reported adverse effects. Caution is advised due to the lack of large-scale clinical trials.

• Researchers observed that BPC-157 activates key biological pathways that promote healing in tissues like tendons.
• The review highlighted that while preclinical studies show strong support for BPC-157's regenerative properties, human data is scarce.
• Only three small pilot studies have been conducted in humans, with no adverse effects reported, but more rigorous research is needed.

HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025

Researchers reviewed studies on BPC-157, a natural peptide that may aid in healing muscles and joints. They found that BPC-157 appears to promote recovery by enhancing growth factors and reducing inflammation, although its safety in humans remains unclear.

• Researchers observed that BPC-157 improved healing outcomes in animal models for muscle, tendon, ligament, and bone injuries.
• In a small human study, 7 out of 12 participants with chronic knee pain reported relief lasting over six months after a single injection.
• While animal studies showed no harmful effects, there is a lack of clinical safety data for humans, raising potential risks.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025

Researchers reviewed the emerging use of injectable peptides, particularly BPC-157, as potential therapies for enhancing recovery and treating joint injuries in athletes. They noted a growing interest in these peptides despite limited clinical research on their effectiveness and safety.

• Researchers observed that BPC-157 shows promise in improving endurance, metabolism, recovery, and tissue repair based on early studies.
• The study highlighted the rapid growth of the therapeutic peptide industry, which is now worth billions, despite a lack of rigorous orthopedic research.
• Researchers emphasized the importance for healthcare professionals to stay informed about the safety, ethics, and regulations surrounding synthetic peptide use in sports and recovery.

Pharmaceuticals (Basel, Switzerland) · 2025

Researchers reviewed the peptide BPC 157, known for its potential health benefits and safety profile. They found that it shows promise in treating various conditions, but it has not yet been approved for medical use due to a lack of comprehensive human studies.

• BPC 157 has demonstrated beneficial effects in preclinical models for conditions like tissue injury and inflammatory bowel disease.
• The compound has a favorable safety profile with few reported side effects, but it was temporarily banned by WADA in 2022.
• Despite its potential, BPC 157 is not approved by the FDA or other regulatory bodies due to insufficient clinical evidence in humans.

Alternative therapies in health and medicine · 2021

Researchers observed that an injection of the peptide BPC 157 may significantly reduce knee pain in patients with various knee conditions. In a small study, 87.5% of participants reported relief from their knee pain after receiving the injection. The findings suggest that BPC 157 could be a promising alternative to traditional treatments like steroids.

• 91.6% of patients receiving only BPC 157 reported significant improvement in knee pain.
• 75% of patients who received a combination of BPC 157 and another peptide showed significant pain relief.
• Overall, 87.5% of participants experienced relief from knee pain with BPC 157 or its combination.

Cell and tissue research · 2019

Researchers reviewed the potential of a peptide called BPC 157 in promoting the healing of soft tissue injuries, such as those affecting tendons and ligaments. They found that BPC 157 showed promising healing effects in animal studies, although its effectiveness in humans is still unproven.

• BPC 157 demonstrated consistent and rapid healing effects for various types of soft tissue injuries in animal models.
• The peptide has shown potential benefits for both traumatic injuries and systemic conditions affecting muscle tissue.
• Few adverse reactions have been reported, but further research is needed to fully understand how BPC 157 works and to confirm its effects in humans.

Current pharmaceutical design · 2018

Researchers reviewed the effects of a peptide called BPC 157 compared to standard growth factors on healing in the gastrointestinal tract and other tissues like tendons and bones. They found that BPC 157 was consistently effective in promoting healing across various injury models, unlike the other growth factors, which showed mixed results.

• BPC 157 was effective in healing injuries in the gastrointestinal tract, including the esophagus, stomach, and intestines.
• In contrast to other growth factors like EGF, FGF, and VEGF, BPC 157 demonstrated consistent healing benefits across multiple tissue types.
• The study highlighted BPC 157's unique role in promoting healing through its own angiogenic effects.

Journal of applied physiology (Bethesda, Md. : 1985) · 2011

Researchers studied the effects of a peptide called BPC 157 on tendon healing in lab settings. They found that BPC 157 significantly promotes the growth and migration of tendon cells, as well as enhances their survival under stress conditions.

• BPC 157 accelerated the outgrowth of tendon cells from tissue samples.
• The peptide increased the survival of tendon cells when exposed to stress.
• BPC 157 enhanced the migration and spreading of tendon cells in a dose-dependent manner.